How to rob the drug king Shumeile 10 billion self-free market?

The market outside the U.S. is being hit by biosypolytes, but sales are still expected to exceed $20 billion by 2020. The strong sales of TNF alpha are still the most successful target for the development of autoimmune diseases, before the emergence of TNF alpha inhibitors, including rheumatoid arthritis, psoriasis and other patients do not have too many drug options, poor quality of life, the current TNFa inhibitors are the big three are AbbVie, Pfizer and Johnson and Johnson, creating a $10 billion autoimmune disease market.
Three TNF alpha antagonists sales In the same kind of drugs occupy the first chair, a drug, four major autoimmune system adaptation, including rheumatoid arthritis, psoriasis arthritis, strong straight spina bifida, Crohn's disease, ulcerative colitis, chronic psoriasis and so on.
, which expired in 2018, has reached patent settlements with several companies in the U.S. market, including Amgen, Samsung Bioepis, Mylan, Freseni Kabi, Novartis Sandoz, Momenta and Pfizer, to ensure that Humira biosynames do not go on the market until 2023.
the first three quarters of 2020, Humira's cumulative sales were $14.68 billion, of which the U.S. market continued to grow, with sales of $11.819 billion , or 8.5 percent, while sales outside the U.S. fell unexpectedly, with sales of $2.861 billion (-14.8 percent).
will put pressure on the AbbVie pipeline, with two other self-free drugs, Skyrizi and Rinvoq, reporting sales of $1,065 million and $1.065 billion in the first three quarters, respectively. The $450 million, which now appears to be performing well in the psoriasis and RA markets respectively, is also beginning to make breakthroughs in different immunologic sub-sectors, including track-crowded psoriasis, inflammatory bowel disease and the emerging admissive dermatitis.
AbbVie's autoimmune pipeline re-establishes the crowded self-free track continues to be snapped up at the track that Has been approved by Symele, and while it's crowded, it doesn't mean there's no chance.
with the further study of disease mechanisms, interletin began to shine in a variety of autoimmune diseases.
is one of the main targets associated with autoimmune diseases, with the three main products being Johnson and Johnson's IL-12/23 inhibitor ustekinumab, Novarma's IL-17A inhibitor Secukinumab, and Lilly's Ixekizumab.
the development of biotherapy for psoriasis from TNFa inhibitors to IL-17, 23, psoriasis area and severity index improvement of 90% or 100% (PASI90/100) has become a number of authoritative guidelines recommended and new drug clinical trials to pursue the goal.
IL-23 currently appears to be the mastermind of plaque-like psoriasis, and an increase in IL-23 concentration activates pathological Th17 cells, while there is no effect on IL-17 physiological concentrations that regulate skin horn formation cells, so IL-23 inhibitors may now appear to be Better options are currently on the market at the latest for AbbVie's Risankizumab, but in the head-to-head trial published earlier this year, Risankizumab was significantly better than secukinumab, with the main effectiveness endpoint PASI 90 rating reaching 87 per cent over 52 weeks.
in plaque-shaped psoriasis trials, Risankizumab's significantly better results than secukinumab Risankizumab's longer-term stability in plaque-like psoriasis are only the first step into the psoriasis market. Faced with the advantages of psoriasis arthritis, which has already been approved by Johnson and Johnson, ustekinumab and Novartis secukinumab, there is more opportunity to capture the market for psoriasis skin and arthritis by simultaneously demonstrating the efficacy of psoriasis skin and arthritis.
In addition to psoriasis, the development of other adaptations of IL-17/IL-23 inhibitors, with different emphasis due to different pharmaceutical companies, Johnson and Johnson chose Crohn's disease and ulcerative colitis, while Novartis and Lilly chose strong spina brysinitis.
Johnson and Johnson has been establishing a market position in the field of inflammatory bowel disease since the treatment of Crohn's signs and symptoms in 1998, and has since been approved for induction and maintenance therapy for Crohn's disease, fistula crohn's disease, and ulcerative colitis, the expansion of these adaptations has made trophics an important treatment for IBS, so subsequent IL-23 products have been extended to IBS first.
Novartis and Lilly's two IL-17 inhibitors are also currently expanding from strong straight spina boutitis (AS) to radiologically negative mid-axis spinal arthritis (nr-axSpA), which increases the opportunity to compete with TNF alpha inhibitors, and neither company currently has a follow-up product layout in the field of spina bnalinitis.
Johnson and Johnson, Novarce and Lilly's self-free pipeline JAK inhibitors to open up a new battleground for self-waiver Inhibition JAK inhibitors has gradually become an important new mechanism for self-free diseases in the past few years, Pfizer in the JAK inhibitor market also took the lead, listed in the United States the first JAK inhibitor tofacit Inib is used for rheumatoid arthritis, but its listing in the EU has been hampered by safety issues - its application for listing was rejected by CHMP in April 2013 and a second application was rejected again in July, until Pfizer's supplementary results were approved in March 2017.
Pfizer has aggressively laid out four JAK inhibitors in the field of dermatology, including Tofacitinib, and is in the late stages of clinical development in terms of different adaptations, including plaque-like psoriasis, inflammatory bowel disease, aditific dermatitis and baldness.
the market potential of Pfizer's autoimmune pipeline specialty dermatitis was only discovered after Sanofi's successful IL-4/13 inhibitor dupilumab, raising the standard of treatment for moderate to severe endexual dermatitis to EASI-1 75 (eczema severity increased by at least 75% from the baseline) became the focus of Sanofi's current autoimmune pipeline, with Pfizer's abrocitinib and AbbVie's Upadacitnib PHASE III trials showing better results.
currently, although baricitinib's efficacy in AD is not particularly bright, on 22 September this year, CHMP received positive feedback in support of its listing in the European Union for the treatment of moderate to severe AD adult patients, and a decision is expected within the next month or two.
if approved, baricitinib is expected to become the first JAK inhibitor to be used to treat AD.
JAK inhibitors and dupilumab for specific dermatitis monopicide efficacy compared to Pfizer's JAK3 inhibitors PF-06651600 and Lilly's Baricitinib in September 2018 and April 2020, the FDA breakthrough therapy for baldness was identified, entering Phase III trial competition, the two sides will seize the first to enter the bald market JAK inhibitors position.
BMS was the first company to bet on the JAK family's highly selective TYK2, announcing on November 4th that TYK2 inhibitor Deucravacitinib (BMS-986165) was in a company called Poetyk-PS O-1's Phase III clinical beat both placebo and PDE4 inhibitor Otezla to reach the double major finish, 16 weeks PASI-75 (defined as pASI increased by at least 75%) and sPGA 0/1 (overall assessed as complete or almost clean).
addition to this, phase II trials of psoriasis arthritis and ulcerative colitis will be conducted.
Not every company can bet on JAK inhibitors, and in August this year, gilgotinib's JAK1 inhibitor, Filgotinib, was rejected for the listing of rheumatoid arthritis (RA) because of reproductive toxicity applications.
the legendary road of the King of Methle may slowly come to an end, but the development of a larger market for self-exemption is only just beginning